Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2019 · 10-K
Revenue$35.44M$35.44M+18.1% vs Q4 2018 Net Income-$102.35M-$102.35MderivedN/M vs Q4 2018 EPS Diluted-$1.60-$1.60N/M vs Q4 2018 Operating Income-$105,929,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
N/M
Operating Cash Flowderived-$93,611,000N/M Free Cash Flowderived-$100,435,000N/M Margins · derivedOperating margin-298.9%+22.2 pt vs Q4 2018
Net margin-288.8%+17.0 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 19, 2020 · 50 d after period end